BRUKER CORPORATION (NASDAQ:BRKR) Files An 8-K Results of Operations and Financial Condition

BRUKER CORPORATION (NASDAQ:BRKR) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Story continues below

On August3, 2017, Bruker Corporation issued a press release announcing combined financial results as of and for the three and six months ended June30, 2017 and providing an updated financial outlook for fiscal 2017. A copy of the press release is attached hereto as Exhibit99.1.

The information in Item 2.02 of this Current Report on Form8-K, including Exhibit99.1, is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information contained in the press release attached hereto as Exhibit99.1, the press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those indicated by these statements. Please refer to the cautionary note contained in the press release under the heading “Forward Looking Statements” for additional information regarding these forward-looking statements.

Section9 — Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Number

99.1

Press release dated August3, 2017.


BRUKER CORP Exhibit
EX-99.1 2 a17-18923_1ex99d1.htm EX-99.1 Exhibit 99.1     Bruker Reports Second Quarter 2017 Financial Results   BILLERICA,…
To view the full exhibit click here

About BRUKER CORPORATION (NASDAQ:BRKR)

Bruker Corporation is a designer and manufacturer of scientific instruments, and analytical and diagnostic solutions. The Company’s operating segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment. The Bruker BioSpin Group segment designs, manufactures and distributes enabling life science tools. The Bruker CALID segment designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as chemical, biological, radiological, nuclear and explosive (CBRNE) detection products. The Bruker Nano segment designs, manufactures and distributes spectroscopy and microscopy instruments. The BEST segment develops and manufactures superconducting and non-superconducting materials and devices.

An ad to help with our costs